Bio Plus Co (099430.KQ) Stock Price

Bio Plus Co Price

CLOSED
3,075.00
​
Market closed

Revenue has compounded at 35.1% per year over the past 7 years to 90.90 B KRW. Earnings per share have grown at 28.6% per year over the last 7 years. Bio Plus Co's net margin stands at 16.5%, down from 28.5% several years earlier. Bio Plus Co currently offers a dividend yield of about 2.28%. The payout ratio is around 29% of earnings. Analysts set a median price target of 9,945.00 KRW, implying 223.4% above the current price. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus.

Bio Plus Co stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio Plus Co business model & stock analysis

BioPlus Co., Ltd. generates revenue through the manufacturing and sale of dermal fillers, primarily hyaluronic acid fillers for temporary facial wrinkle improvement. The company also produces and sells anti-adhesion agents to prevent surgical adhesions, biomaterials for joint tissue repair, and other tissue restoration products. These products are supplied to medical professionals and healthcare facilities requiring cosmetic and surgical solutions. The firm targets the medical and cosmetic sectors, focusing on tissue restoration applications for both aesthetic and functional needs. The company's product portfolio includes biomaterials for tissue restoration, specifically designed for temporary facial wrinkle correction, anti-adhesion solutions for surgical sites, and joint tissue repair materials. These offerings cater to healthcare providers seeking advanced biomaterials for patient care. BioPlus Co., Ltd. serves the medical industry by providing specialized products that address both cosmetic enhancement and post-surgical recovery requirements. BioPlus Co., Ltd. operates within the biomaterials sector, focusing on dermal fillers and tissue repair solutions. Its products are utilized by medical practitioners for facial aesthetics and surgical applications. The company's revenue streams are derived from direct sales of these biomaterial products to healthcare institutions and professionals in the medical field.

Frequently asked questions about Bio Plus Co

Analysts currently set an average price target of 9,945.00 KRW for the Bio Plus Co stock (median: 9,945.00 KRW), implying +223.4 % versus the latest price. The consensus is based on 5 analyst ratings.

5 analysts currently rate the Bio Plus Co stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Bio Plus Co to generate revenue of 120.60 B KRW and earnings per share of 587.10 KRW.

Converted at the current exchange rate, the Bio Plus Co share trades at 2.05 EUR (3,075.00 KRW).

The expected revenue of Bio Plus Co is 120.60 B KRW. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Bio Plus Co is 36.13 B KRW. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Bio Plus Co is currently 5.24. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Bio Plus Co stock.

The price-to-sales ratio (P/S) of Bio Plus Co is currently 1.57. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Bio Plus Co stock.

The Eulerpool Quality Score for Bio Plus Co is 4/10.

The ISIN of Bio Plus Co is KR7099430001. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Bio Plus Co is 099430.KQ. The ticker symbol is used to trade Bio Plus Co shares on the stock exchange.

Fair ValueTerminal
2,583.00 KRW
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Equipment & Supplies
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
South Korea
Currency
KRW
Initial public offering
Sep 27, 2021
ISIN
KR7099430001
Cusip
Y3R50M108
Market capitalization
185.79 B KRWLarge Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
5.14
P/Ee 2027
4.73
P/S
P/Se
1.57
EV/EBIT
11.26
P/B Ratio
1.06
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
8.37 %
Dividend
Dividend yield
2.28 %
Est. Dividend Yield
4.68 %
Payout Ratio
28.72 %
Dividend growth Ø5Y
—
Dividend payments per year
1
Dividend paid since
4 years
Dividend not reduced since
1 year
Dividend increased since
1 year
Dividend withholding tax
22.00 %
Last updated Nov 11, 2026, 8:50 AM

Bio Plus Co Peer Group

Bio Plus Co FIGI

099430:KS · BBG0125CXPF4099430:KQ · BBG0125CXPH2

All fundamentals and in-depth analysis of Bio Plus Co

Our stock analysis for Bio Plus Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bio Plus Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.